Literature DB >> 1868458

Accumulation of m-iodobenzylguanidine by neuroblastoma cells results from independent uptake and storage mechanisms.

P G Montaldo1, M Lanciotti, A Casalaro, P Cornaglia-Ferraris, M Ponzoni.   

Abstract

The modalities of uptake and storage of iodine-labeled m-iodobenzylguanidine (MIBG) by four human neuroblastoma cell lines have been studied. SK-N-BE(2)C cell line has been shown to possess the specific (type 1) MIBG uptake, as well as an efficient extravesicular storage mechanism. Conversely, LAN-5 cells, which show a nonsaturation kinetic of MIBG incorporation, lack only the ability to efficiently store the MIBG taken up by a mechanism that can be pharmacologically defined as uptake 1. The two other neuroblastoma cell lines tested, GI-LI-N and GI-CA-N, lack both uptake and storage capacity. In view of the fact that the only detailed study on specific MIBG uptake by a human neuroblastoma cell line has been carried out on SK-N-SH, a highly heterogeneous cell line, our report provides new insights on the molecular and cellular pharmacology of radiolabeled MIBG.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1868458

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  11 in total

Review 1.  Radioiodinated metaiodobenzylguanidine: a review of its biodistribution and pharmacokinetics, drug interactions, cytotoxicity and dosimetry.

Authors:  A R Wafelman; C A Hoefnagel; R A Maes; J H Beijnen
Journal:  Eur J Nucl Med       Date:  1994-06

2.  Interferon-γ-induced differentiation of human neuroblastoma cells increases cellular uptake and halflife of metaiodobenzylguanidine.

Authors:  P G Montaldo; R Carbone; P Cornaglia Ferraris; M Ponzoni
Journal:  Cytotechnology       Date:  1993-01       Impact factor: 2.058

3.  Clinical Applications and the Roles of Transporters in Disposition, Tumor Targeting, and Tissue Toxicity of meta-Iodobenzylguanidine (mIBG).

Authors:  Antonio J Lopez Quiñones; Leticia Salvador Vieira; Joanne Wang
Journal:  Drug Metab Dispos       Date:  2022-02-22       Impact factor: 3.579

Review 4.  Radiolabeled metaiodobenzylguanidine for the treatment of neuroblastoma.

Authors:  Steven G DuBois; Katherine K Matthay
Journal:  Nucl Med Biol       Date:  2008-08       Impact factor: 2.408

5.  Meta-[131I]iodobenzylguanidine uptake and meta-[211At]astatobenzylguanidine treatment in human medulloblastoma cell lines.

Authors:  D K Strickland; G Vaidyanathan; H S Friedman; M R Zalutsky
Journal:  J Neurooncol       Date:  1995       Impact factor: 4.130

6.  Regression of orthotopic neuroblastoma in mice by targeting the endothelial and tumor cell compartments.

Authors:  Dieter Fuchs; Rolf Christofferson; Mats Stridsberg; Elin Lindhagen; Faranak Azarbayjani
Journal:  J Transl Med       Date:  2009-03-12       Impact factor: 5.531

7.  131I-metaiodobenzylguanidine (131I-MIBG) therapy for residual neuroblastoma: a mono-institutional experience with 43 patients.

Authors:  A Garaventa; O Bellagamba; M S Lo Piccolo; C Milanaccio; E Lanino; L Bertolazzi; G P Villavecchia; M Cabria; G Scopinaro; F Claudiani; B De Bernardi
Journal:  Br J Cancer       Date:  1999-12       Impact factor: 7.640

8.  131I-meta-iodobenzylguanidine therapy in neuroblastoma spheroids of different sizes.

Authors:  M N Gaze; R J Mairs; S M Boyack; T E Wheldon; A Barrett
Journal:  Br J Cancer       Date:  1992-12       Impact factor: 7.640

9.  Localisation of [131I]MIBG in nude mice bearing SK-N-SH human neuroblastoma xenografts: effect of specific activity.

Authors:  G Vaidyanathan; H S Friedman; S T Keir; M R Zalutsky
Journal:  Br J Cancer       Date:  1996-05       Impact factor: 7.640

10.  Prediction of accumulation of 131I-labelled meta-iodobenzylguanidine in neuroblastoma cell lines by means of reverse transcription and polymerase chain reaction.

Authors:  R J Mairs; A Livingstone; M N Gaze; T E Wheldon; A Barrett
Journal:  Br J Cancer       Date:  1994-07       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.